Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phase Forward establishes subsidiary in India
Phase Forward has worked with several partners and sponsors in the region for the last seven years to support several hundred hosted clinical trials. While expanding in India,
Phase Forward has worked with several partners and sponsors in the region for the last seven years to support several hundred hosted clinical trials. While expanding in India,
The total number of shares sold by the company included 1.8 million shares sold to the underwriters upon their exercise of their over-allotment option in full. Certain selling
Through its strategic in-licensing and development strategy, Reliant has developed a portfolio of specialty medicines combating heart disease, including US rights to Lovaza (omega-3-acid ethyl esters), a treatment
The acquisition is a two-step process. The initial E42.3 million cash payment will purchase the privately held Carli family interest in Ideal Medical Products, and then a tender
CooperVision had alleged that CIBA Vision infringed patented technologies relating to the edge design and rotational stabilization of contact lenses while CIBA Vision alleged that CooperVision infringed patented
This industrialization model is Institute of Microbiology, Chinese Academy of Sciences’s (IMCAS’s) first cooperative arrangement with a pharmaceuticals manufacturing company. Genesis will fund the industrialization model’s daily operations
The payments will be made in increments of $1 million upon the achievement of various equity financing parameters which may be met by SagaX over a four-year period
The preliminary results from the first 21 patients treated in the Phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease
Labopharm initiated the formal dispute resolution process in October 2007 after receiving an approvable letter from the FDA for its once-daily formulation of tramadol in May. The FDA
Following the expiration of the exclusive supply contract, Span-America will be able to sell its proprietary PressureGuard CFT therapeutic support surfaces to non Hill-Rom customers, and Hill-Rom will